DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 088292
NDA 088292 describes IMIPRAMINE HYDROCHLORIDE, which is a drug marketed by Novartis, Leading Pharma Llc, Lederle, Lupin Ltd, Oxford Pharms, Par Pharm, Roxane, Sandoz, Specgx Llc, Sun Pharm Industries, Teva, Usl Pharma, Vangard, Watson Labs, and West Ward, and is included in thirty-six NDAs. It is available from fifteen suppliers. Additional details are available on the IMIPRAMINE HYDROCHLORIDE profile page.
The generic ingredient in IMIPRAMINE HYDROCHLORIDE is imipramine hydrochloride. There are thirty-four drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the imipramine hydrochloride profile page.
The generic ingredient in IMIPRAMINE HYDROCHLORIDE is imipramine hydrochloride. There are thirty-four drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the imipramine hydrochloride profile page.
Summary for 088292
| Tradename: | IMIPRAMINE HYDROCHLORIDE |
| Applicant: | Par Pharm |
| Ingredient: | imipramine hydrochloride |
| Patents: | 0 |
| Therapeutic Class: | Antidepressants |
| Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 088292
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IMIPRAMINE HYDROCHLORIDE | imipramine hydrochloride | TABLET;ORAL | 088292 | ANDA | KAISER FOUNDATION HOSPITALS | 0179-0118 | N | 0179-0118-70 |
| IMIPRAMINE HYDROCHLORIDE | imipramine hydrochloride | TABLET;ORAL | 088292 | ANDA | Par Pharmaceutical, Inc. | 49884-054 | N | 49884-054-10 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Oct 21, 1983 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
